What is the mechanism of Semaglutide 99% powder?
Technical characteristics and mechanism of Semaglutide powder
1. Molecular structure and physical and chemical properties
Semaglutide is a synthetic glucagon-like peptide -1 analog. Its molecular formula is CHNO, its relative molecular weight is about 4113.58 Da, and its CAS number is 910463-68-2.
It is white to white-like solid at room temperature, so Semaglutide 99% powder is recommended to store it in dry and dark conditions to maintain its chemical stability. In terms of solubility, the solubility in DMSO is about 5 mg/mL, and that in water is about 3.85 mg/mL (usually ultrasonic assistance is needed). It is suggested that the prepared solution be stored at-80 C (6 months) or-20 C (1 month) separately to avoid repeated freezing and thawing.
2. Multiple mechanisms of action
As a long-acting GLP-1 receptor agonist, its mechanism of action is diverse and efficient. First of all, it can promote insulin secretion and inhibit glucagon secretion in a glucose concentration-dependent manner, thus reducing blood sugar levels without increasing the risk of hypoglycemia. Secondly, it can delay gastric emptying, suppress appetite and regulate energy balance by acting on the central nervous system, which is also the basis of its remarkable weight loss effect.
It is worth noting that recent studies have found that it also has multiple benefits beyond reducing blood sugar and weight. Preclinical studies have shown that Semaglutide can enhance autophagy, inhibit oxidative stress and apoptosis, and regulate mitochondrial function and lipid metabolism (such as reducing de novo fat production in liver). In the field of neuroscience, it shows neuroprotective potential, such as improving motor function and reducing α -synuclein aggregation in Parkinson's disease model. In addition, the study also found that it can improve hepatic steatosis and has therapeutic potential for metabolic-related fatty liver disease.
The latest mechanism research also shows that Semaglutide 99% powder can directly act on the central nervous system through the blood-brain barrier, which may be the key to its multiple benefits. Preclinical studies show that it can significantly improve the survival rate of SH-SY5Y neuroblastoma cells and increase the expression of autophagy-related proteins, thus protecting nerve cells by enhancing autophagy and inhibiting apoptosis.
Semaglutide 99% powder process and quality control system
1. Technical route of synthesis process
Its production mainly adopts solid-phase polypeptide synthesis technology, which is a complex and delicate process. The synthesized crude peptide needs to be purified by high performance liquid chromatography to remove impurities such as deleted sequence fragments and side reaction products. The purified Semaglutide also needs to be modified by fatty acid side chain, which is the key step to realize its long-term characteristics-to enhance its binding ability with albumin and thus prolong its half-life.
The main challenges faced by mass production include racemization control, sequence integrity assurance and impurity spectrum control. The leading enterprises in the industry ensure that the products meet the medical standards by optimizing the selection of activators, controlling the reaction temperature and real-time monitoring. In addition, the residual solvents and metal impurities need to be strictly controlled in the production process to ensure the safety and stability of the final product.
2. Quality control system and standards
Its quality control covers many dimensions such as physical and chemical characteristics, purity and biological activity. According to the standard of pharmaceutical raw materials, its HPLC purity is usually required to reach more than 99%. Quality control methods include reversed-phase HPLC and liquid chromatography-mass spectrometry to identify the identity and purity of products; Peptide map analysis ensures the correct amino acid sequence; Residual solvents, water content and bacterial endotoxin should also meet strict standards.
Application fields and research results
1. Research on treatment of metabolic diseases.
The most mature application field of Semaglutide is the treatment and research of type 2 diabetes and obesity. A large number of clinical studies have confirmed that it can significantly reduce glycosylated hemoglobin and body weight of patients with type 2 diabetes. Based on the strong evidence of clinical trials, Semaglutide 99% powder has been approved by many countries for type 2 diabetes and obesity.
2. Exploration of emerging application fields
In recent years, the research scope of Semaglutide has gone beyond metabolic diseases and expanded to many emerging fields. In the study of neurodegenerative diseases, it shows the potential to improve the motor function of Parkinson's disease model and reduce the aggregation of α -synuclein. In the research of Alzheimer's disease,
In the field of liver disease research, preclinical studies show that it can reduce body weight, blood sugar and serum liver enzymes, reduce triglyceride deposition in liver, and improve hepatic steatosis and ballooning of hepatocytes in mice with fatty liver disease related to metabolic dysfunction. In addition, the study also found that Semaglutide can down-regulate the markers of de novo lipogenesis Acaca and Scd1.
Industry development trend and future prospect
1. The direction of technological innovation
In the expansion of new indications, neurodegenerative diseases (such as Alzheimer's disease and Parkinson's disease), nonalcoholic fatty liver disease/fatty liver disease related to metabolic dysfunction, cardiovascular diseases and some cancer types have become research hotspots. These explorations are expected to greatly expand its market space and clinical value.
2. Production process innovation and capacity expansion
Facing the increasing market demand, the production process of Semaglutide is continuously optimized, and new technologies such as green synthesis, continuous flow production and biocatalysis are being introduced into the field of polypeptide drug production. These innovations are aimed at improving productivity, reducing costs and reducing environmental impact.
Capacity expansion is another significant trend in the industry. Digitalization and automation technology are also changing the production process of Semaglutide 99% powder. Process control, online analysis technology and digital quality management system driven by artificial intelligence are gradually applied in the field of polypeptide synthesis to improve production efficiency and product consistency. These technological innovations are expected to further reduce the production cost of Semaglutide and improve its accessibility.
conclusion
Semaglutide powder, as an outstanding representative of polypeptide drugs, not only revolutionized the treatment mode of metabolic diseases, but also promoted the innovative development of the entire pharmaceutical industry. From molecular design to production technology, from quality control to clinical application, Semaglutide embodies the latest technological achievements in the field of polypeptide drugs.
With the deepening of scientific research, its application prospect is expanding from the traditional treatment of diabetes and obesity to new fields such as neurodegenerative diseases, fatty liver diseases and cardiovascular protection. At the same time, the continuous innovation of production technology and the continuous expansion of production capacity are expected to improve its accessibility. In the future, with the deepening of the understanding of receptor signaling pathway, the innovation of dosage form technology and the development of individualized medicine, it is expected to play a greater role in the era of precision medicine.
Xi'an Faithful BioTech Co., Ltd. combines cutting-edge production technology with comprehensive quality assurance to provide high-quality Semaglutide 99% powder that meets international pharmaceutical standards. Our commitment to excellent, competitive prices and technical support makes us the preferred partner of global healthcare providers and researchers. Please contact our technical team in sales11@faithfulbio.com to find out how our products can improve your formula.
This is a list of the names of the core scientific research documents that I referred to and relied on in the process of writing a soft article. These documents provide solid scientific evidence for the efficacy and mechanism mentioned in this paper.
Kevin Cowart et al., Ann Pharmacother. 2020
Lau J, et al. "Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide." J Med Chem. 2015
Zhang L. et al., Neuropeptides. 2018
The study of Nature Communications also involves the safety and efficacy of Semaglutide in non-arteritis anterior ischemic optic neuropathy.
Wilding et al. reported the efficacy of weekly regimen of Semaglutide in overweight/obese adults in the New England Journal of Medicine.
Chen X. et al., Front Pharmacol. 2023
Sorli C. et al., Lancet Diabetes Endocrinol., 2017（SUSTAIN 1）
Molecules, 2024，29(16):3909（Shapira-Furman T. et al.）
Front Pharmacol., 2023（Chen X. et al.）
